等待开盘 04-01 09:30:00 美东时间
+0.540
+1.63%
今日重点评级关注:Oppenheimer:维持Alumis"跑赢大市"评级,目标价从50美元升至55美元;美银证券:维持Rocket Pharmaceuticals"买入"评级,目标价从8美元升至9美元
03-31 16:30
RBC Capital analyst Steven Shemesh reiterates Valvoline (NYSE:VVV) with a Outperform and maintains $46 price target.
03-31 00:40
今日重点评级关注:HC Wainwright & Co.:维持Perspective Therapeutics"买入"评级,目标价从12美元升至13美元;Litchfield Hills:维持Star Equity Holdings"买入"评级,目标价从21美元升至28美元
03-24 10:07
Stifel analyst Chris O'Cull upgrades Valvoline (NYSE:VVV) from Hold to Buy and raises the price target from $40 to $42.
03-24 00:16
今日重点评级关注:HC Wainwright & Co.:维持NovoCure"买入"评级,目标价从39美元升至47美元;HC Wainwright & Co.:维持Agios制药"买入"评级,目标价从62美元升至65美元
02-13 15:30
Top Wall Street analysts changed their outlook on these top names. For a comple...
02-12 22:21
今日重点评级关注:HC Wainwright & Co.:维持NovaBridge Biosciences"买入"评级,目标价从7美元升至9美元;Truist Securities:维持Reddit"买入"评级,目标价从270美元升至275美元
02-09 14:37
今日重点评级关注:康托·菲茨杰拉德:维持Wave Life Sciences Ltd."超配"评级,目标价从34美元升至41美元;Piper Sandler:维持Replimune Group"超配"评级,目标价从13美元升至14美元
02-06 16:52
华盛资讯2月6日讯,胜牌公布2025财年Q4业绩,公司Q4营收4.62亿美元,同比增长11.5%,归母净利润亏损0.33亿美元,由盈转亏。
02-06 07:02
Wells Fargo analyst David Lantz maintains Valvoline (NYSE:VVV) with a Overweight and raises the price target from $38 to $40.
02-05 21:50